Applying the Partial Order Continual Reassessment Method to High-Dimensional Treatment Combinations.

Area of Science:

• Clinical Trials
• Biostatistics
• Pharmacology

Background:

• Combination therapies are increasingly popular, complicating Phase I clinical trial design.
• The Partial Ordering Continual Reassessment Method (POCRM) is adaptable but under-explored for more than two drugs.
• Specifying toxicity orderings in high-dimensional settings is challenging due to combinatorial complexity.

Purpose of the Study:

• To propose a systematic approach for specifying toxicity orderings in Phase I trials involving more than two drugs.
• To enhance the design and performance of the Partial Ordering Continual Reassessment Method (POCRM) for complex combination therapies.

Main Methods:

• Developed a novel ordering specification method based on asymptotic properties.
• Applied the method to Phase I clinical trial designs with combinations of more than two drugs.
• Conducted extensive simulation studies to evaluate the proposed method.

Main Results:

• The proposed systematic approach effectively specifies toxicity orderings in high-dimensional settings.
• The novel ordering specification method demonstrates improved design performance.
• Simulations show benefits both asymptotically and with finite sample sizes.

Conclusions:

• The new method provides a robust framework for designing Phase I trials with complex drug combinations.
• This systematic approach addresses the limitations of existing methods for multi-drug therapies.
• The findings suggest enhanced efficiency and reliability in early-phase cancer drug development.